Targeting B cells for treatment of systemic sclerosis
- PMID: 37540776
- DOI: 10.1097/BOR.0000000000000961
Targeting B cells for treatment of systemic sclerosis
Abstract
Purpose of review: The pathogenesis of systemic sclerosis (SSc) has been linked to dysfunctional B cells as demonstrated in previous research. This review aims to show the evidence and ongoing clinical trials of B cell-targeted therapy and overview the various aspects of B cell involvement in SSc.
Recent findings: We provide an overview of the current understanding and therapeutic strategies targeting B cells in SSc patients. Several molecular targets of B cells have been identified for treating SSc, including CD20, CD19, B-cell activating factor (BAFF), and proteasome.
Summary: Many clinical trials have demonstrated that B cells play a critical role in the pathogenesis of SSc and may be a potential therapeutic target to improve disease symptoms. Although large-scale clinical studies are needed, various B cell-targeted therapies have the potential to address the unmet needs of SSc patients.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers 2015; 1:15002.
-
- Asano Y. Systemic sclerosis. J Dermatol 2018; 45:128–138.
-
- Denton CP, Khanna D. Systemic sclerosis. Lancet 2017; 390:1685–1699.
-
- Lafyatis R, O’Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007; 56:3167–3168.
-
- Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci 2003; 100:12319–12324.
Publication types
MeSH terms
LinkOut - more resources
Research Materials